Targeting inflammatory microenvironments: overcoming therapy resistance and immunosuppression
Top Cited Papers
Open Access
- 17 February 2026
- journal article
- review article
- Published by Springer Nature in Molecular Cancer
- Vol. 25 (1)
Abstract
Chronic inflammation within the tumor microenvironment (TME) is a critical driver of immune evasion, resistance to therapy, and progression of cancer, whilKeywords
Funding Information
- General Program of National Natural Science Foundation of China (No. 82204948, 82174243)
- the Fundamental Research Funds for the Central Universities (No. 90011461220755)
- High Level Key Discipline of National Administration of Traditional Chinese Medicine - Traditional Chinese constitutional medicine (zyyzdxk-2023251)
- MOE Pioneering Project for Disciplinary Breakthroughs
This publication has 269 references indexed in Scilit:
- Bispecific Antibody Targeting VEGF/TGF‐β Synergizes with Local Radiotherapy: Turning Tumors from Cold to Inflamed and Amplifying Abscopal EffectsAdvanced Science, 2025
- Optimizing Early Clinical Investigations in Cancer Immunotherapy: The Translational Journey of RG6292, a Novel, Selective Treg‐Depleting AntibodyClinical Pharmacology & Therapeutics, 2024
- Immunologic tumor microenvironment modulators for turning cold tumors hotCancer Communications, 2024
- Correlation and efficacy of TACE combined with lenvatinib plus PD‐1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological featuresCancer Medicine, 2023
- Metabolic response to radiation therapy in cancerMolecular Carcinogenesis, 2021
- Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatmentMolecular Oncology, 2021
- Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic proceduresAmerican Journal of Hematology, 2021
- Role of IL-6 in dendritic cell functionsJournal of Leukocyte Biology, 2021
- Pegilodecakin as monotherapy or in combination with anti‐PD‐1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I studyInternational Journal of Cancer, 2021
- Myeloid-Derived Suppressor Cells in the Tumor Microenvironment2020